Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

News

Biogen defends $30m drug

Posted 18 June 2021 AM

Biogen is suing India-based generic outfit MSN Laboratories which is planning to launch a generic copy of one of Biogen's most successful properties, MS drug Tecfidera.

In an action launched by Biogen in the Federal Court, it has alleged MSN and Australian company Accelagen are threatening its Tecfidera patent by launching a generic version before the 29 October 2024 patent expiry, according to legal publication Lawyerly.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs